Table 2 The drugs targeting Hippo pathway in clinical trials
From: The Hippo signalling pathway and its implications in human health and diseases
Mechanism | Name (sponsor) | Phase | Indications | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
TEAD palmitoylation inhibition | VT3989 (Vivace Therapeutics) | Phase 1 | Solid Tumour Mesothelioma | NCT04665206 |
IK-930 (Ikena Oncology) | Phase 1 | Solid Tumours Mesothelioma Epithelioid Hemangioendothelioma NF2 Deficiency YAP1 or TAZ Gene Fusions | NCT05228015 | |
YAP antisense oligonucleotide | ION537 (Ionis Pharmaceuticals) | Phase 1 | Advanced solid tumours | NCT04659096 |
Not been disclosed | IAG933 (Novartis) | Phase 1 | Mesothelioma | NCT04857372 |
